areteiatx.comHealthcare / BioTech & PharmaFounded: 2022Funding to Date: $600MM
Areteia Therapeutics is a clinical stage biotechnology company focused on oral asthma drug development.
Funding Date | Share Class | Amount Raised | Price per Share | Post-Money Valuation | Key Investors | |
---|---|---|---|---|---|---|
02/13/2024 | Series A-3 (NV) | $153.76MM | $xx.xx | $1.55B | Access Biotechnology, Arch Venture Partners, Bain Capital Life Sciences, Gv, Marshall Wace, Maverick Capital, Population Health Partners, Sanofi, Saturn Partners, Viking Global Investors | |
Price per Share
$xx.xx
Shares Outstanding
15,376,018
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
6.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Access Biotechnology, Arch Venture Partners, Bain Capital Life Sciences, Gv, Marshall Wace, Maverick Capital, Population Health Partners, Sanofi, Saturn Partners, Viking Global Investors
|
||||||
02/13/2024 | Series A-1 | $153.76MM | $xx.xx | $1.55B | Access Biotechnology, Arch Venture Partners, Bain Capital Life Sciences, Gv, Marshall Wace, Maverick Capital, Population Health Partners, Sanofi, Saturn Partners, Viking Global Investors | |
Price per Share
$xx.xx
Shares Outstanding
15,376,018
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
6.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Access Biotechnology, Arch Venture Partners, Bain Capital Life Sciences, Gv, Marshall Wace, Maverick Capital, Population Health Partners, Sanofi, Saturn Partners, Viking Global Investors
|
||||||
02/13/2024 | Series A-4 (NV) | $58.74MM | $xx.xx | $1.55B | Access Biotechnology, Arch Venture Partners, Bain Capital Life Sciences, Gv, Marshall Wace, Maverick Capital, Population Health Partners, Sanofi, Saturn Partners, Viking Global Investors | |
Price per Share
$xx.xx
Shares Outstanding
4,518,448
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
6.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Access Biotechnology, Arch Venture Partners, Bain Capital Life Sciences, Gv, Marshall Wace, Maverick Capital, Population Health Partners, Sanofi, Saturn Partners, Viking Global Investors
|
||||||
02/13/2024 | Series A-2 | $58.74MM | $xx.xx | $1.55B | Access Biotechnology, Arch Venture Partners, Bain Capital Life Sciences, Gv, Marshall Wace, Maverick Capital, Population Health Partners, Sanofi, Saturn Partners, Viking Global Investors | |
Price per Share
$xx.xx
Shares Outstanding
4,518,448
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
6.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Access Biotechnology, Arch Venture Partners, Bain Capital Life Sciences, Gv, Marshall Wace, Maverick Capital, Population Health Partners, Sanofi, Saturn Partners, Viking Global Investors
|